Clinical Trials · NCT00306748
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ironwood Pharmaceuticals, Inc.
- Enrollment
- 40
- Start date
- Mar 2006
- Locations
- 14 sites, United States
- Primary endpoint
- Safety will be evaluated on an ongoing basis by completing physical examinations, ECGs, clinical laboratory tests, and adverse event reporting.